# Tredegar Investments

> Tredegar Investments is a VC fund backing Biotechnology and Medical. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Richmond, United States
- Total investments: 8
- Last investment: Apr 2001
- Lead investor: 13%
- Last updated: Aug 2026
- Website: http://www.tredegar.com

Tredegar Investments is a company producing plastic films and aluminum extrusions and also invests in internet start-ups.

## Contacts

5 contacts available for Tredegar Investments. Shizune tracks 1 team members at Tredegar Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/tredegar-investments?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 38% |
| Medical | 2 | 25% |
| Health Care | 2 | 25% |
| Pharmaceutical | 2 | 25% |
| Cooking | 1 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 38% |
| Series C | 3 | 38% |
| Funding Round | 2 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John Steitz | President and Chief Executive Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Fast Track | Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision:to revolutionize the management of clinical trials. | $30.1M | Series C | Apr 26, 2001 |  |
| Locus Pharmaceuticals | Locus Pharmaceuticals, Inc. develops a drug design and development platform for oral drug therapies in the areas of unmet medical needs. Its fragment-based computational drug design technology is used for the discovery and development of compounds for the treatment of unmet medical needs. The company has a computational drug design technology,which is used to develop a pipeline of drug development candidates, including direct and allosteric kinase inhibitors for cancer and inflammation diseases. Locus Pharmaceuticals, Inc. was formerly known as Locus Discovery, Inc. The company was incorporated in 1998 and is based in Blue Bell, Pennsylvania. Locus Pharmaceuticals, Inc. is a former subsidiary of Sarnoff Corporation. | $42.8M | Series B | Nov 28, 2000 |  |
| Novalux | Novalux develops, manufactures, and distributes laser systems. The company offers Novalux Extended Cavity Surface Emitting Laser, a surface-emitting semiconductor laser. Its products are used in various applications, such as projection display, specialty lighting, neon sign alternative lighting, and automotive lighting. The company was founded in1998 and is headquartered in Sunnyvale, California. As of January 8, 2008, Novalux, Inc. operates as a subsidiary of Arasor International Limited. | $109M | Series C | Sep 26, 2000 |  |
| Fast Track | Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision:to revolutionize the management of clinical trials. | $15.6M | Series B | Apr 05, 2000 |  |
| Illumina | Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, andcomplete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998. | $28M |  | Jan 10, 2000 |  |
| Cooking.com | Cooking.com sells more than 90,000 kitchen products, all backed by a 100% satisfaction guarantee. In addition to being a store, the site has a large collection of recipes and community features. The company was founded by a team who previously worked together at The Walt Disney Corporation.Cooking.com also operates online stores for many bigbrands including | $30M | Series C | Oct 01, 1999 |  |
| Ceptyr | Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development. | $11.5M |  | Aug 18, 1999 |  |
| Cooking.com | Cooking.com sells more than 90,000 kitchen products, all backed by a 100% satisfaction guarantee. In addition to being a store, the site has a large collection of recipes and community features. The company was founded by a team who previously worked together at The Walt Disney Corporation.Cooking.com also operates online stores for many bigbrands including | $16M | Series B | Apr 01, 1999 |  |

8 of 8 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [Lombard Odier](https://shizune.co/investors/profile/lombard-odier) — VC Fund, 3 deals together
- Vanguard Ventures — VC Fund, 3 deals together
- [Chase Capital Partners](https://shizune.co/investors/profile/chase-capital-partners) — VC Fund, 2 deals together
- Dynafund Ventures — VC Fund, 2 deals together
- [Idealab](https://shizune.co/investors/profile/idealab) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Tredegar Investments invest in?

Tredegar Investments invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Tredegar Investments?

Public channels for Tredegar Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Tredegar Investments?

The team at Tredegar Investments includes John Steitz (President and Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co